SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending due to a contentious short report from Muddy Waters, which has triggered heavy selling volume and intense debate among retail investors. The community remains deeply divided, with many traders dismissing the report as a coordinated "short and distort" tactic to facilitate short covering, while others express growing concern over the potential impact of the allegations on management's credibility.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing extreme volatility driven by a massive insider share purchase by the CEO and growing investor anticipation regarding a potential partnership with OpenAI. The community remains deeply divided, with some traders viewing these catalysts as a long-term bottoming signal, while others criticize the company's executive compensation and struggle to reconcile the positive news with the stock's persistent intraday sell-offs.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus fueled by a flurry of strategic acquisitions and a high-profile partnership with Palantir that has bolstered its status as an emerging defense prime. While the stock experiences significant intraday volatility and selling pressure, the community remains heavily bullish, fixated on the upcoming earnings report and the company's potential to secure major government defense contracts in an increasingly drone-centric global threat landscape.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing increased investor activity as the market prepares for quarterly earnings, with the community actively speculating on potential buyout rumors and monitoring the ramp-up of BRIUMVI sales. Investors are particularly focused on company revenue guidance and the progress of the subcutaneous pipeline as catalysts that could influence the stock's current trading range.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending following a massive $27 billion AI infrastructure deal with Meta, which effectively cements its status as a leading hyperscaler. While the stock initially surged, it faced downward pressure due to the announcement of a $3.75 billion convertible senior notes offering, sparking intense debate among investors over whether the move represents necessary capital-intensive growth or dilutive overreach.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing a volatile and high-momentum market debut as investors speculate on its drone autonomy software, which has gained attention for its reported real-world combat application. The community remains sharply divided, with some betting on a parabolic "low-float" squeeze driven by defense industry demand, while others caution against potential hype-driven instability and speculative valuations.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is facing heightened volatility as traders weigh strong product milestones in AI data center infrastructure against recent insider selling and broader market rotation out of high-growth semiconductor plays. The community is actively debating the stock's future, with many interpreting recent sharp price swings as manipulative shakeouts while bulls focus on the company's long-term potential in AI connectivity.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors weigh strong demand for its GLP-1 franchise against intense market competition and analyst downgrades regarding valuation and addressable market size. The community remains highly focused on the company's upcoming pipeline catalysts, specifically the anticipated approval of its oral weight-loss drug, while debating whether recent share price volatility represents a buying opportunity or a correction from previous overvaluation.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is at the center of investor focus following a massive cross-border bond sale aimed at fueling an aggressive AI infrastructure and data center expansion. While shareholders are monitoring the stock's volatility amidst rising geopolitical tensions and energy costs, community sentiment remains heavily polarized between those prioritizing the long-term potential of AWS and logistics dominance, and others expressing frustration with the stock's recent price stagnation.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending as investors digest a major $2.4 billion contract to provide 1.2 gigawatts of power generation for AI data centers, a deal widely viewed as a transformational catalyst for the company. The community is actively discussing the stock's role in the AI infrastructure and power generation sector, with many dismissing recent short-seller reports as manipulation and focusing instead on a strong project pipeline and potential for significant long-term growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cantor Fitzgerald L. P. Invests $1.58 Million in Bicara Therapeutics Inc. $BCAX

Cantor Fitzgerald L. P. purchased a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the third quarter, according to its most recent disclosure with the Securities...

Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference

Bicara Therapeutics (NASDAQ:BCAX) is developing tumor-targeting bifunctional antibodies, with its lead candidate ficerasfusp alfa designed to address both EGFR and TGF-beta biology in cancer, company...

Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $704,804.22 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 36,766 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of...

Claire Mazumdar Sells 36,766 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 36,766 shares of the company's stock in a transaction on Monday, March 9th. The stock was sold at an average price of...

Bicara Therapeutics (NASDAQ:BCAX) Reaches New 1-Year High - Here's What Happened

Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year High - Still a Buy...

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 1,786 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock in a transaction that occurred on Thursday, March 5th. The shares were sold...

Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $49,278.63 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 2,631 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of...

Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $33,469.64 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 1,786 shares of the business's stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an...

Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 3,817 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 3,817 shares of the stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price...

Ivan Hyep Sells 13,555 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 13,555 shares of the business's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an...

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

BCAX
Bicara Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BCAX News

BCAXBicara Therapeutics